Your browser doesn't support javascript.
loading
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 variants
Zhi-Nan Chen; Ping Zhu; Huijie Bian; Jiejie Geng; Liang Chen; Yufeng Yuan; Ruo Chen; Ke Wang; Yongqiang Deng; Peng Du; Jiangning Liu; Guizhen Wu; Youchun Wang; Xiuxuan Sun; Ting Guo; Xu Yang; Jiao Wu; Jianli Jiang; Ling Li; Kui Zhang; Hua Zhu; Zhaohui Zheng; Xianghui Fu; Fengfan Yang; Xiaochun Chen; Hao Tang; Zheng Zhang; Ding Wei; Yang Zhang; Ying Shi; Yumeng Zhu; Zhuo Pei; Fei Huo; Shirui Chen; Qingyi Wang; Wen Xie; Yirong Li.
Afiliación
  • Zhi-Nan Chen; The Fourth Military Medicial University
  • Ping Zhu; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
  • Huijie Bian; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Jiejie Geng; Fourth Military Medical University
  • Liang Chen; School of Medicine, Shanghai University
  • Yufeng Yuan; Zhongnan Hospital of Wuhan University
  • Ruo Chen; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Ke Wang; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Yongqiang Deng; Beijing Institute of Microbiology and Epidemiology
  • Peng Du; Beijing Institute of Biotechnology
  • Jiangning Liu; Institute of Laboratory Animals Science, Chinese Academy of Medical Sciences
  • Guizhen Wu; MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC
  • Youchun Wang; National Institutes for Food and Drug Control
  • Xiuxuan Sun; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Ting Guo; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Xu Yang; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Jiao Wu; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Jianli Jiang; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Ling Li; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Kui Zhang; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
  • Hua Zhu; Institute of Laboratory Animals Science, Chinese Academy of Medical Sciences
  • Zhaohui Zheng; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
  • Xianghui Fu; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
  • Fengfan Yang; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
  • Xiaochun Chen; Jiangsu Pacific Meinuoke Biopharmceutical Co. Ltd.
  • Hao Tang; Jiangsu Pacific Meinuoke Biopharmceutical Co. Ltd.
  • Zheng Zhang; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Ding Wei; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Yang Zhang; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Ying Shi; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Yumeng Zhu; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Zhuo Pei; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Fei Huo; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Shirui Chen; National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University
  • Qingyi Wang; Department of Foreign Languages, Fourth Military Medical University
  • Wen Xie; Zhongnan Hospital of Wuhan University
  • Yirong Li; Zhongnan Hospital of Wuhan University
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-444111
ABSTRACT
SARS-CoV-2 and its variants are raging worldwide. Unfortunately, the global vaccination is not efficient enough to attain a vaccine-based herd-immunity and yet no special and effective drug is developed to contain the spread of the disease. Previously we have identified CD147 as a novel receptor for SARS-CoV-2 infection. Here, we demonstrated that CD147 antibody effectively inhibits infection and cytokine storm caused by SARS-CoV-2 variants. In CD147KO VeroE6 cells, infections of SARS-CoV-2, its variants (B.1.1.7, B.1.351) and pseudovirus mutants (B.1.1.7, B.1.351, B.1.525, B.1.526 (S477N), B.1.526 (E484K), P.1, P.2, B.1.617.1, B.1.617.2) were decreased. Meanwhile, CD147 antibody effectively blocked the entry of variants and pseudomutants in VeroE6 cells, and inhibited the expression of cytokines. A model of SARS-CoV-2-infected hCD147 transgenic mice was constructed, which recapitulated the features of exudative diffuse alveolar damage and dynamic immune responses of COVID-19. CD147 antibody could effectively clear the virus and alveolar exudation, resolving the pneumonia. We found the elevated level of cyclophilin A (CyPA) in plasma of severe/critical cases, and identified CyPA as the most important proinflammatory intermediate causing cytokine storm. Mechanistically, spike protein of SARS-CoV-2 bound to CD147 and initiated the JAK-STAT pathway, which induced expression of CyPA. CyPA reciprocally bound to CD147, triggered MAPK pathway and consequently mediated the expression of cytokine and chemokine. In conclusion, CD147 is a critical target for SARS-CoV-2 variants and CD147 antibody is a promising drug to control the new wave of COVID-19 epidemic.
Licencia
cc_no
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Experimental_studies / Observational_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Experimental_studies / Observational_studies Idioma: En Año: 2021 Tipo del documento: Preprint